WO2008050362A3 - Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies - Google Patents

Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies Download PDF

Info

Publication number
WO2008050362A3
WO2008050362A3 PCT/IT2007/000676 IT2007000676W WO2008050362A3 WO 2008050362 A3 WO2008050362 A3 WO 2008050362A3 IT 2007000676 W IT2007000676 W IT 2007000676W WO 2008050362 A3 WO2008050362 A3 WO 2008050362A3
Authority
WO
WIPO (PCT)
Prior art keywords
allergies
medicament
prevention
preparation
treatment
Prior art date
Application number
PCT/IT2007/000676
Other languages
French (fr)
Other versions
WO2008050362A2 (en
Inventor
Luigina Romani
Francesco Bistoni
Enrico Garaci
Guido Rasi
Vallebona Paola Sinibaldi
Original Assignee
Sigma Tau Ind Farmaceuti
Luigina Romani
Francesco Bistoni
Enrico Garaci
Guido Rasi
Vallebona Paola Sinibaldi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti, Luigina Romani, Francesco Bistoni, Enrico Garaci, Guido Rasi, Vallebona Paola Sinibaldi filed Critical Sigma Tau Ind Farmaceuti
Priority to CA002666562A priority Critical patent/CA2666562A1/en
Priority to US12/447,156 priority patent/US20090270594A1/en
Priority to EA200900603A priority patent/EA200900603A1/en
Priority to JP2009534060A priority patent/JP2010507649A/en
Priority to AU2007310415A priority patent/AU2007310415A1/en
Priority to BRPI0718019-5A priority patent/BRPI0718019A2/en
Priority to MX2009004237A priority patent/MX2009004237A/en
Priority to EP07827727A priority patent/EP2083847A2/en
Publication of WO2008050362A2 publication Critical patent/WO2008050362A2/en
Publication of WO2008050362A3 publication Critical patent/WO2008050362A3/en
Priority to IL198290A priority patent/IL198290A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns the use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies
PCT/IT2007/000676 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies WO2008050362A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002666562A CA2666562A1 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies
US12/447,156 US20090270594A1 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies
EA200900603A EA200900603A1 (en) 2006-10-27 2007-09-27 APPLICATION OF THYMOSINE ALPHA-1 FOR OBTAINING A MEDICINE FOR PREVENTION AND TREATMENT OF ALLERGIC REACTIONS
JP2009534060A JP2010507649A (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 to prepare a medicament for the prevention and treatment of allergies
AU2007310415A AU2007310415A1 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies
BRPI0718019-5A BRPI0718019A2 (en) 2006-10-27 2007-09-27 USE OF ALPHA 1 TIMOSINE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF ALLERGIES.
MX2009004237A MX2009004237A (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies.
EP07827727A EP2083847A2 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies
IL198290A IL198290A0 (en) 2006-10-27 2009-04-22 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000583A ITRM20060583A1 (en) 2006-10-27 2006-10-27 USE OF THE TIMAMA ALFA 1 FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION AND CARE OF ALLERGIES
ITRM2006A000583 2006-10-27

Publications (2)

Publication Number Publication Date
WO2008050362A2 WO2008050362A2 (en) 2008-05-02
WO2008050362A3 true WO2008050362A3 (en) 2008-07-10

Family

ID=39322638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2007/000676 WO2008050362A2 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies

Country Status (13)

Country Link
US (1) US20090270594A1 (en)
EP (1) EP2083847A2 (en)
JP (1) JP2010507649A (en)
KR (1) KR20090092267A (en)
CN (1) CN101626778A (en)
AU (1) AU2007310415A1 (en)
BR (1) BRPI0718019A2 (en)
CA (1) CA2666562A1 (en)
EA (1) EA200900603A1 (en)
IL (1) IL198290A0 (en)
IT (1) ITRM20060583A1 (en)
MX (1) MX2009004237A (en)
WO (1) WO2008050362A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087067A2 (en) * 2003-03-28 2004-10-14 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
AR020102A1 (en) * 1998-07-30 2002-04-10 Ucb Sa COMPOSITE FOR THE PREVENTION AND / OR TREATMENT OF ALLERGY; PHARMACEUTICAL COMPOSITION, COSMETIC COMPOSITION, COMPOSITION IN THE FORM OF DRINK, FOOD AND / OR FOOD FOR DOMESTIC ANIMALS THAT INCLUDES IT AND USE OF SUCH COMPOUND OR SUCH PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A FOOD
US20060121029A1 (en) * 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087067A2 (en) * 2003-03-28 2004-10-14 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMLIE-LEFOND ET AL: "Innate immunity for biodefense: A strategy whose time has come", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 116, no. 6, 1 December 2005 (2005-12-01), pages 1334 - 1342, XP005198337, ISSN: 0091-6749 *
C. MONTAGNOLI ET AL: "Immunity and Tolerance to Aspergillus Involve Functionally Distinct Regulatory T Cells and Tryptophan Catabolism", JOURNAL OF IMMUNOLOGY, vol. 176, no. 3, February 2006 (2006-02-01), pages 1712 - 1723, XP002478988 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 31 January 1983 (1983-01-31), ZAWISZA E ET AL: "[Thymosin (TFX-Polfa) in the treatment of hay fever]", XP002479425, Database accession no. NLM6346287 *
L. ROMANI ET AL: "Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance", BLOOD, vol. 108, no. 7, 1 October 2006 (2006-10-01), pages 2265 - 2274, XP002478987 *
POLSKI TYGODNIK LEKARSKI (WARSAW, POLAND : 1960) 31 JAN 1983, vol. 38, no. 5, 31 January 1983 (1983-01-31), pages 153 - 154, ISSN: 0032-3756 *
ROMANI L ET AL: "Thymosin 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 103, no. 11, 1 June 2004 (2004-06-01), pages 4232 - 4239, XP002903606, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
IL198290A0 (en) 2011-08-01
MX2009004237A (en) 2009-07-07
ITRM20060583A1 (en) 2008-04-28
KR20090092267A (en) 2009-08-31
CA2666562A1 (en) 2008-05-02
US20090270594A1 (en) 2009-10-29
JP2010507649A (en) 2010-03-11
EA200900603A1 (en) 2009-10-30
EP2083847A2 (en) 2009-08-05
BRPI0718019A2 (en) 2013-11-19
AU2007310415A1 (en) 2008-05-02
CN101626778A (en) 2010-01-13
WO2008050362A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
IL177914A0 (en) Use of indazolecarboxamide derivatives for the preparation of a medicament that is intended for the treatment and prevention of paludism
TWI369210B (en) Use of lgg in the manufacture of a medicament for the prevention or treatment of respiratory allergies
EP1985302A4 (en) Medicament for treatment of tumor and the use thereof
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
EP1940361A4 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
HK1108168A1 (en) Vaccine for prevention and treatment of hiv-infection
IL207439B (en) Use of an anti-calcitonin gene-related peptide (cgrp) antagonist antibody for the manufacture of a medicament for the prevention and/or treatment of arthritic pain
EP2099449A4 (en) Pharmaceutical composition for the treatment and prevention of diseases involving impotence
HK1129594A1 (en) Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
IL210589A (en) Use of a tuberculosis rv2386c protein in the manufacture of a medicament for the treatment or prevention of tuberculosis
HK1244819A1 (en) Foxm1 peptide and medicinal agent comprising the same
IL189162A0 (en) Use of hydroxybenzoic acid ester and analogues for the manufacture of a medicament for the prevention and treatment of virus infection
EP2813223B8 (en) Metal delivery agents and therapeutic uses of the same
HRP20130622T1 (en) Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1814567A4 (en) Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections
GB2443336B (en) Spiruchostatin analogues and their medicinal use
IL189270A0 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
IL197766A0 (en) Use of oritavancin for the prevention and treatment of anthrax
HK1111599A1 (en) Pharmaceutical compositions for the treatment of cellulite
IL195955A0 (en) Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
EP2005964A4 (en) The medicament for treating hyperphospheremia and preparation thereof
WO2008157365A3 (en) Vinylazacycloalkanes for treating neuropathic pain
WO2008050362A3 (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780039959.4

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2666562

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020097008098

Country of ref document: KR

Ref document number: MX/A/2009/004237

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 198290

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2009534060

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007827727

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2881/CHENP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200900603

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2007310415

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007310415

Country of ref document: AU

Date of ref document: 20070927

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827727

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12447156

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0718019

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090427